Eargo

Eargo, Inc. is engaged in the development of hearing aids and headsets solutions. Its products include Eargo Neo HiFi, Eargo Neo, Eargo Max, and Eargo Accessories. The company was founded by Florent Michel, Raphael Michel, and Daniel Shen on November 12, 2010 and is headquartered in San Jose, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Earnings data Q3 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Eargo reports robust Q4 earnings, eyes growth through innovation

Eargo's Q4 2022 performance showcased strong revenue growth and improved gross margins, supported by successful fundraising efforts. The company's innovative product launches and strategic partnerships position it well for future growth.
While facing challenges in operational areas and economic uncertainties, Eargo's focus on refining strategies, accessing new markets, and driving innovation presents opportunities for sustained growth and market leadership.

Eargo reports robust Q1 earnings, eyes growth amidst industry evolution

Eargo's Q1 performance reflects growth momentum, positive customer reception, and strategic advancements in its business model.
While challenges like cash burn improvement and competition exist, Eargo's strengths in strategy execution and market positioning bode well for future success.
Opportunities in partnerships, market expansion, and innovation position Eargo favorably for continued growth and industry leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eargo will provide customers with even more over-the-counter (OTC) choices to help address hearing loss on their own terms Eargo will provide customers with even more over-the-counter (OTC) choices to help address hearing loss on their own terms

Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eargo, Inc. (NasdaqGS: EAR) to an affiliate of Patient Square Capital. Under the terms of the proposed transaction, shareholders of Eargo will receive $2.55 in cash for each share of Eargo that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet.

EARGO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eargo, Inc. - EAR

NEW YORK , Dec. 19, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Eargo, Inc. ("Eargo" or the "Company") (NASDAQ: EAR) stock prior to October 30 th, 2023 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Eargo, Inc. with an affiliate of Patient Square Capital (or "Patient Square").

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Eargo, Inc.

NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Wolf Popper LLP is investigating claims on behalf of investors in Eargo, Inc. (NASDAQ:EAR) concerning the acquisition of Eargo by its controlling shareholder, Patient Square Capital. Under the terms of the acquisition, Eargo shareholders would receive $2.55 per share in cash.

Wolf Popper LLP Investigates the Acquisition of Eargo, Inc. by Its Controlling Shareholder, Patient Square Capital

LOS ANGELES, CA / ACCESSWIRE / November 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Eargo, Inc. ("Eargo" or "the Company") (NASDAQ:EAR) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Eargo board breached its fiduciary duties to shareholders in relation to its approval of the acquisition of the Company by Patient Square Capital.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Eargo, Inc. ("Eargo" or "the Company") (NASDAQ:EAR) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Eargo board breached its fiduciary duties to shareholders in relation to its approval of the acquisition of the Company by Patient Square Capital.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo”) celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission.

Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

MILWAUKEE , Oct. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating Eargo (Nasdaq: EAR) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square Capital. Click here to learn how to join the action https://www.ademilaw.com/case/eargo-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Eargo, Inc. has obtained a Fair Price in its transaction with Patient Square Capital

Eargo (NASDAQ: EAR ) stock is jumping more than 50% on Oct. 30 after the company agreed to be taken private by Patient Square Capital . The deal is valued at $53 million.

Why Is Eargo (EAR) Stock Up 50% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Eargo, Inc. (NASDAQ: EAR) to an affiliate of Patient Square Capital for $2.55 per share in cash is fair to Eargo shareholders. Halper Sadeh encourages Eargo shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Eargo.

EAR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Eargo, Inc. Is Fair to Shareholders

SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues its mission to make hearing wellness more accessible, reaching more people where they are across the country.

Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

Eargo, Inc. (NASDAQ:EAR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Nick Laudico - Chief Retail Officer Christian Gormsen - President, Chief Executive Officer & Director Adam Laponis - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Operator Ladies and gentlemen, good afternoon. My name is Abby, and I will be your conference operator today.

Eargo, Inc. (EAR) Q1 2023 Earnings Call Transcript

Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-year Gross systems shipped of 8,705, up 51% year-over-year GAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022 Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023 Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”), a medical device company on a mission to improve hearing health, today reported its financial results for the first quarter ended March 31, 2023.

Eargo Reports First Quarter 2023 Financial Results

Eargo, Inc. (NASDAQ:EAR ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Nick Laudico - Chief Retail Officer Christian Gormsen - President and Chief Executive Officer and Director Adam Laponis - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to the Eargo, Inc. Fourth Quarter 2022 Earnings Conference Call. I would now like to turn the call over to Nick Laudico, Chief Retail Officer.

Eargo, Inc. (EAR) Q4 2022 Earnings Call Transcript

Eargo Reports Fourth Quarter 2022 Financial Results

SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.

Eargo to Report Fourth Quarter 2022 Financial Results on March 23, 2023

Eargo, Inc. went public in October 2020, raising approximately $141 million in a U.S. IPO. The firm sells advanced hearing aid products in the United States.

Eargo Seeks To Reignite Revenue Growth After Major Stumble

SAN JOSE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, announced today that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated February 1, 2023 informing Eargo that the Company's minimum bid price deficiency has been cured.

Nasdaq Confirms Eargo's Minimum Bid Price Deficiency is Cured

SAN JOSE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company's common stock (the “Reverse Stock Split”).

Eargo Effects 1-for-20 Reverse Stock Split

SAN JOSE, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Wednesday, January 18, 2023, under the existing trading symbol “EAR” and a new CUSIP number: 270087208.

Eargo to Complete a 1-for-20 Reverse Stock Split

Numerous companies at CES 2023 have jumped into the potentially lucrative market for over-the-counter hearing aids, including Eargo, Jabra and Nuheara. The post Over-The-Counter Hearing Aids Something To Shout About appeared first on Investor's Business Daily.

Over-The-Counter Hearing Aids Something To Shout About

NationsBenefits to Sell Eargo Hearing Aids Over-The-Counter (OTC) beginning January 1, 2023 NationsBenefits to Sell Eargo Hearing Aids Over-The-Counter (OTC) beginning January 1, 2023

Eargo and NationsBenefits Announce Strategic Partnership

FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--NationsBenefits®, a leading provider of supplemental benefits, flex cards, and member engagement solutions for health plans, and Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced a strategic partnership. The partnership will allow health plan members served by NationsBenefits to use their plan benefit towards purchasing Eargo Over-the-Counter (OTC) hearing aids starting on January 1, 2023.

NationsBenefits and Eargo Announce Partnership to Offer Over-the-Counter Hearing Aids

SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022.

News for Eargo Stock (EAR)